Table 1.

Multivariate analysis for the outcome of sorafenib treatment with the use of Cox proportional-hazard model

	Hazard Ratio (95% CI)	P Value
A: Progression-free Survival
Vitamin K dosing	0.16 (0.08 - 0.32)	<0.001
Child-Pugh status (A vs. B)	0.95 (0.46 - 1.95)	0.88
ECOG performance status (0 vs. 1 or 2)	0.86 (0.45 - 1.61)	0.64
Extrahepatic spread	0.96 (0.54 - 1.71)	0.89
Macroscopic vascular invasion	2.55 (1.34 - 4.82)	0.004
Age	0.97 (0.94 - 1.00)	0.06
Initial dose of sorafenib	0.65 (0.35 - 1.21)	0.18
B: Overall Survival
Vitamin K dosing	0.38 (0.20 - 0.73)	0.003
Child-Pugh status (A vs. B)	0.77 (0.34 - 1.75)	0.53
ECOG performance status (0 vs. 1 or 2)	0.36 (0.17 - 0.73)	0.005
Extrahepatic spread	1.42 (0.75 - 2.71)	0.28
Macroscopic vascular invasion	3.81 (2.00 - 7.26)	<0.001
Age	1.01 (0.98 - 1.05)	0.60
Initial dose of sorafenib	1.01 (0.54 - 1.89)	0.98

ECOG: Eastern Cooperative Oncology Group.